Filing Flows › Corcept Therapeutics (CORT) › Q3 2026
Corcept Therapeutics (CORT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Corcept Therapeutics (CORT) reported revenue of $340M for the third quarter 2026 (Q3 2026), +64% from a year earlier and +33% from the quarter before. Operating margin was 33.7%, net earnings $127M (37.2% of revenue).
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $340M | +33% | +64% |
| Operating profit | $115M | +178% | 11× |
| Net earnings | $127M | +195% | +545% |
| Operating cash flow | $143M | +326% | +162% |
| Free cash flow | $142M | +358% | +161% |
What changed
Revenue was $340.5M in Q3 2026, up 64% year over year and up 33% from the previous quarter. Hypercortisolism Products was the largest line at 73% of revenue. Hypercortisolism Products added $41.4M year over year (up 20%), 31% of the total change.
Operating profit was $114.7M, a 33.7% margin (up 28.8 points year over year). Of the extra revenue versus Q3 2025, 79% reached operating profit, above the 5% margin then. Total costs grew 14% against revenue growth of 64%. The fastest-growing cost line was SG&A (+33%). Net earnings were $126.8M, up 545% year over year. The effective tax rate was -5.4%.
Operating cash flow was $142.9M (up 162% year over year), 113% of net earnings. Non-cash charges added back $1.0M of depreciation and amortization and $29.4M of share-based compensation. Working capital and other items used $14.4M. Capital expenditures of $709K left free cash flow of $142.2M.
Questions
What was Corcept Therapeutics' revenue in the third quarter 2026?
Corcept Therapeutics (CORT) reported revenue of $340M for the third quarter 2026 (Q3 2026), +64% from a year earlier and +33% from the quarter before.
Was Corcept Therapeutics profitable in the third quarter 2026?
Operating profit was $115M (33.7% of revenue) and net earnings $127M.